关于PARP抑制剂组合策略的最新情况
Zhuoqun Lin1, Lingfang Wang2, Ziyu Xing1
1Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cancer control : journal of the Moffitt Cancer Center
|November 5, 2024
概括
PARP 抑制剂在癌症治疗中表现有前途,特别是在缺乏 HRR 的瘤中. 与其他疗法的结合旨在提高疗效并克服耐药性,尽管仍然存在挑战.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- PARP 抑制剂已经改变了癌症治疗,特别是对于具有同源复合修复 (HRR) 缺陷的瘤 (例如,BRCA1/2突变).
- 限制包括耐药性,毒性和在缺乏同源重组缺陷 (HRD) 的患者中有效性有限.
- 目前正在探索组合策略,以提高PARP抑制剂的有效性并扩大患者的适用性.
研究的目的:
- 审查PARP抑制剂的机制和局限性.
- 探索涉及PARP抑制剂的组合治疗方法.
- 总结最近的研究,并讨论这些组合的临床疗效.
主要方法:
- 对PARP抑制剂机制和局限性的文献综述.
- 分析组合策略,包括免疫检查点抑制剂,抗血管原剂和小分子抑制剂.
- 综合了关于组合疗法的最近临床研究数据.
主要成果:
- PARP 抑制剂对HRR缺乏癌症有效,但面临着耐药性和毒性等挑战.
- 与其他药物的组合显示出改善结果和克服耐药性的潜力.
- 在研究中有效性的变化和重叠的毒性需要仔细考虑.
结论:
- 了解PARP抑制机制对于开发有效的组合疗法至关重要.
- 组合策略为优化癌症治疗和扩大患者人群提供了一个有希望的途径.
- 需要进一步的研究来完善组合方法并减轻相关的毒性.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
Base Excision Repair
22.1K
One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
The first step of...
22.1K


